Concomitant use of tamoxifen and endoxifen in postmenopausal early breast cancer: prediction of plasma levels by physiologically-based pharmacokinetic modeling

Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation

(2013) Ulrich M. Zanger et al.   PHARMACOLOGY & THERAPEUTICS

The Role of Physiologically Based Pharmacokinetic Modeling in Regulatory Review

(2012) S-M Huang et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Regulatory Experience With Physiologically Based Pharmacokinetic Modeling for Pediatric Drug Trials

(2012) R Leong et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Best Practice in the Use of Physiologically Based Pharmacokinetic Modeling and Simulation to Address Clinical Pharmacology Regulatory Questions

(2012) P Zhao et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Pharmacogenomics of Codeine, Morphine, and Morphine-6-Glucuronide

(2012) Thomas Eissing et al.   Molecular Diagnosis & Therapy

Dose-adjustment study of tamoxifen based on CYP2D6 genotypes in Japanese breast cancer patients

(2011) Kazuma Kiyotani et al.   BREAST CANCER RESEARCH AND TREATMENT

Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients

(2011) Joanne S. L. Lim et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Physiologically based pharmacokinetic modelling of high- and low-dose etoposide: from adults to children

(2011) Gisela Kersting et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Increasing Tamoxifen Dose in Breast Cancer Patients Based on CYP2D6 Genotypes and Endoxifen Levels: Effect on Active Metabolite Isomers and the Antiestrogenic Activity Score

(2011) M F Barginear et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Activity Levels of Tamoxifen Metabolites at the Estrogen Receptor and the Impact of Genetic Polymorphisms of Phase I and II Enzymes on Their Concentration Levels in Plasma

(2011) T E Mürdter et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Tamoxifen Metabolite Concentrations, CYP2D6 Genotype, and Breast Cancer Outcomes

(2011) L Madlensky et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Genotype-Guided Tamoxifen Dosing Increases Active Metabolite Exposure in Women With Reduced CYP2D6 Metabolism: A Multicenter Study

(2011) William J. Irvin et al.   JOURNAL OF CLINICAL ONCOLOGY

Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer

(2010) Jennifer Gjerde et al.   BMC CANCER

Endoxifen, a New Cornerstone of Breast Cancer Therapy: Demonstration of Safety, Tolerability, and Systemic Bioavailability in Healthy Human Subjects

(2010) A Ahmad et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Significant Effect of Polymorphisms inCYP2D6andABCC2on Clinical Outcomes of Adjuvant Tamoxifen Therapy for Breast Cancer Patients

(2010) Kazuma Kiyotani et al.   JOURNAL OF CLINICAL ONCOLOGY

The Tamoxifen Metabolite, Endoxifen, Is a Potent Antiestrogen that Targets Estrogen Receptor   for Degradation in Breast Cancer Cells

(2009) X. Wu et al.   CANCER RESEARCH

Pharmacogenomics of Tamoxifen Therapy

(2009) H. Brauch et al.   CLINICAL CHEMISTRY

Risk to the Breast-Fed Neonate From Codeine Treatment to the Mother: A Quantitative Mechanistic Modeling Study

(2009) S Willmann et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Physiology-Based Simulations of a Pathological Condition

(2008) Andrea N Edginton et al.   CLINICAL PHARMACOKINETICS